Drug Trial Radar · NCT07212426
Efficacy, Safety, and Pharmacokinetics of LP-005 Injection in PNH Patients.
Last checked: Nov 19, 2026Latest source record: Jan 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
30
Actual
Start
Nov 14, 2024
Primary completion
May 6, 2026
Study completion Mar 31, 2028
Sponsor
- Lead sponsor
- Longbio PharmaIndustry
- Sponsor type
- Industry
- First posted
- Oct 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, open-label, Phase II clinical study to evaluate the efficacy, safety, and pharmacokinetics of LP-005 injection in adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
Conditions
- PNH - Paroxysmal Nocturnal Hemoglobinuria
Interventions
LP-005 InjectionBiological
IV infusion, Q4W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in serum lactate dehydrogenase (LDH) levels.Time frame: Baseline and at Week 12.
- Proportion of participants with ≥2 g/dL increase in hemoglobin level from Baseline in the absence of transfusion.Time frame: Baseline and at Week 24.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Nanjing Medical University
Nanjing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.